Hiers Paul S, Rohrs Henry J
AACE Clin Case Rep. 2020 Aug 6;6(6):e326-e329. doi: 10.4158/ACCR-2020-0103. eCollection 2020 Nov-Dec.
Acrodysostosis is a rare skeletal dysplasia with one gene mutation associated with pseudohypoparathyroidism. We describe a 15-year-old male patient with genetic acrodysostosis who presented with hyperparathyroidism.
Laboratory testing, including genetic testing for acrodysostosis and biochemical evaluation for hypercalcemia, were obtained. For evaluation of the source of hyperparathyroidism, parathyroid imaging including technetium (99mTc) sestamibi (MIBI) scan, ultrasound, and 4-dimensional computed tomography scans were performed.
The initial calcium level of 11.7 mg/dL (reference range is 8.4 to 10.2 mg/dL), phosphorus of 2.6 mg/dL (reference range is 2.9 to 5.0 mg/dL), and parathyroid hormone (PTH) of 177 pg/mL (reference range is 15 to 65 pg/mL) were suspicious for hyperparathyroidism. Magnesium, albumin, creatinine, and PTH-related peptide levels were normal. His calcium/creatinine ratio was 0.15, calcium/creatinine clearance ratio was 0.008, and the fractional excretion of phosphorus was 34%. Our patient had no symptoms other than long-standing bone pain. Thyroid ultrasound then MIBI scan did not show a parathyroid adenoma or parathyroid gland hyperplasia. Familial hypocalciuric hypercalcemic syndrome was entertained, but without a family history and documented normal calcium levels throughout childhood, it was considered unlikely. On subsequent testing, his calcium and PTH levels increased. Subsequent imaging including repeat thyroid ultrasound, MIBI scan, and computed tomography did not find a definitive cause. Multiple endocrine neoplasia type 1 genetic testing was negative. Without an adenoma seen to remove surgically, we performed a trial of cinacalcet with successful reduction in PTH and normalization of his calcium and phosphorus levels.
Pseudohypoparathyroidism and hypocalcemia are well reported in acrodysostosis. To the best of our knowledge, this is the first reported case of hypercalcemia caused by hyperparathyroidism in a patient with acrodysostosis.
肢端发育不全是一种罕见的骨骼发育不良,有一种基因突变与假性甲状旁腺功能减退相关。我们描述了一名15岁的男性遗传性肢端发育不全患者,其出现了甲状旁腺功能亢进。
进行了实验室检查,包括肢端发育不全的基因检测和高钙血症的生化评估。为评估甲状旁腺功能亢进的来源,进行了甲状旁腺成像,包括锝(99mTc)甲氧基异丁基异腈(MIBI)扫描、超声和四维计算机断层扫描。
初始血钙水平为11.7mg/dL(参考范围为8.4至10.2mg/dL),血磷为2.6mg/dL(参考范围为2.9至5.0mg/dL),甲状旁腺激素(PTH)为177pg/mL(参考范围为15至65pg/mL),怀疑为甲状旁腺功能亢进。镁、白蛋白、肌酐和PTH相关肽水平正常。他的钙/肌酐比值为0.15,钙/肌酐清除率为0.008,磷的分数排泄率为34%。除长期骨痛外,我们的患者没有其他症状。甲状腺超声检查后进行的MIBI扫描未显示甲状旁腺腺瘤或甲状旁腺增生。考虑了家族性低钙血症性高钙血症综合征,但由于没有家族史且记录显示其儿童期血钙水平正常,因此认为可能性不大。在后续检查中,他的钙和PTH水平升高。包括重复甲状腺超声、MIBI扫描和计算机断层扫描在内的后续成像未发现明确病因。多发性内分泌腺瘤1型基因检测为阴性。由于未发现可手术切除的腺瘤,我们进行了西那卡塞试验,成功降低了PTH水平,并使他的钙和磷水平恢复正常。
肢端发育不全中假性甲状旁腺功能减退和低钙血症有充分报道。据我们所知,这是首例报道的肢端发育不全患者因甲状旁腺功能亢进导致高钙血症的病例。